XARELTO® (rivaroxaban)

XARELTO - Pivotal Clinical Trial Publications

RECORD1-4

Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358(26):2765-2775.

Kakkar AK, Brenner B, Dahl OE, et al; for the RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double blind, randomized controlled trial. Lancet. 2008;372:31-39. 4.

Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.

Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-1680.

ROCKET AF

Patel MR, Mahaffey KW, Garg J, et al; for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.

EINSTEIN DVT, EINTSTEIN PE, EINSTEIN Extension

Bauersachs R, Berkowitz SD, Brenner B, et al; on behalf of the EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.

Büller HR, Prins MH, Lensing AWA, et al; on behalf of the EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297.

EINSTEIN CHOICE

Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211-1222.

COMPASS

Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330.

VOYAGER PAD

Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020a;382(21):1994-2004.

MAGELLAN

Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-523.

Spyropoulos AC, Lipardi C, Xu J, et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study. Clin Appl Thromb Hemost. 2019;25:1-9.

EINSTEIN Junior

Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomized, controlled phase 3 trial. Lancet Haematol. 2020;7(1):e18-e27.

UNIVERSE

McCrindle BW, Michelson AD, Van Bergen AH, et al. Thromboprophylaxis for children post-fontan procedure: insights from the UNIVERSE study. J Am Heart Assoc. 2021;10(22):e021765.

Medical Inquiries

Locate My Medical Science Liaison

Chat Live

Available Monday - Friday 9AM - 4:30PM ET

Call Me Now

Available Monday - Friday 9AM - 8PM ET

Email Your Inquiry

Call 1-800-JANSSEN

Available Monday - Friday 9AM - 8PM ET

Live Video

Available Monday - Friday 9AM - 4:30PM ET